|
1) Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008; 358: 2355-65
|
|
|
|
2) Richards JB, Rivadeneira F, Inoue M, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet. 2008; 371: 1505-12
|
|
|
|
|
|
3) Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009; 360: 2426-37
|
|
|
|
|
|
4) Cauley JA, LaCroix AZ, Cummnings SR, et al. Serum 25-hydroxyvitamin D concentrations and risk of hip fracture. Ann Intern Med. 2008; 149: 242-50
|
|
|
|
|
|
5) Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009; 169: 551-61
|
|
|
|
|
|
6) Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009 Apr 15; (2) CD007146
|
|
|
|
|
|
7) Von Friesendorff M, Besjakov J, Akesson K. Long-term survival and fracture risk after hip fracture: a 22-year follow-up in women. J Bone Miner Res. 2008; 23: 1832-41
|
|
|
|
|
|
8) Cauley JA, Lui LY, Barnes D, et al; SOF Research Group. Successful skeletal aging: a marker of low fracture risk and longevity. The Study of Osteo-porotic Fractures (SOF). J Bone Miner Res. 2009; 24: 134-43
|
|
|
|
|
|
9) Von Muhlen D, Safii S, Jasal SK, et al. Asso-ciations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteopor Int. 2007; 18: 1337-44
|
|
|
|
|
|
10) Berg KM, Kunins HV, Jackson JL, et al. Asso-ciation between alcohol consumption and both osteoporotic fracture and bone density. Am J Med. 2008; 121: 406-18
|
|
|
|
|
|
11) Cummings SR, San Martin J, McClung MR, et al; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteo-porosis. N Engl J Med. 2009; 361: 756-65
|
|
|
|
|
|
12) Smith MR, Egerdie B, Hernández Toriz N, et al; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-depri-vation therapy for prostate cancer. N Engl J Med. 2009; 361: 745-55
|
|
|
|
|
|
13) Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009; 24: 153-61
|
|
|
|
|
|
14) http://www.amgen.com/media/media_pr_detail.jsp？releaseID＝1316081
|
|
|
|
|
|
15) Anastasilakis AD, Toulis KA, Goulis DG, et al. Efficacy and safety of denosumab in post-menopausal women with osteopenia or osteo-porosis: a systematic review and a meta-analysis. Horm Metab Res. 2009; 41: 721-9
|
|
|
|
|
|
16) Matsumoto T, Hagino H, Shiraki M, et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with estab-lished osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int. 2009; 20: 1429-37
|
|
|
|
|
|
17) Hagino H, Nishizawa Y, Sone T, et al. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone. 2009; 44: 1078-84
|
|
|
|
|
|
18) Harris ST, Reginster JY, Harley C, et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) data-base fracture study. Bone. 2009; 44: 758-65
|
|
|
|
|
|
19) Lewiecki EM, Keaveny TM, Kopperdahl D, et al. Once-monthly oral ibandronate improves bio-mechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2008; 94: 171-80
|
|
|
|
|
|
20) Lyles KW, Eriksen EF, Boonen S, et al; for the HORIZON Recurrent Fracture Trial. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007; 357: 1799-809
|
|
|
|
|
|
21) Grey A, Bolland MJ, Wattie D, et al. The antiresorptive effects of a single dose of zoledro-nate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009; 94: 538-44
|
|
|
|
|
|
22) Reid DM, Devogelaer JP, Saag K, et al; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised con-trolled trial. Lancet. 2009; 373: 1253-63
|
|
|
|
|
|
23) Gallagher AM, Riebrock S, Staa TP, et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008; 23: 1569-75
|
|
|
|
|
|
24) Curtis JR, Westfall AO, Saag KG, et al. Risk of hipfracture after bisphosphonate discontinuation: importants for a drug holiday. Osteopor Int. 2008; 19: 1613-20
|
|
|
|
|
|
25) Cadarette SM, Katz JN, Brookhart MA, et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med. 2008; 148: 637-46
|
|
|
|
|
|
26) Lindsay R, Miller P, Pohl G, et al. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int. 2009; 20: 943-8
|
|
|
|
|
|
27) Cosman F, Nieves JW, Zion M, et al. Retreatment with teriparatide one year after the first teripara-tide course in patients on continued long-term alendronate. J Bone Miner Res. 2009; 24: 1110-5
|
|
|
|
|
|
28) Black DM, Bouxsein ML, Palermo L, et al; PTH Once-Weekly Research (POWR) Group. Random-ized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab. 2008; 93: 2166-72
|
|
|
|
|
|
29) Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteo-porosis. N Engl J Med. 2004; 350: 459-68
|
|
|
|
|
|
30) Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 2009; 24: 1358-68
|
|
|
|
|
|
31) Brufsky A, Bundred N, Coleman R, et al; Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adju-vant letrozole. Oncologist. 2008; 13: 503-14
|
|
|
|
|
|
32) Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premeno-pausal breast cancer. N Engl J Med. 2009; 360: 679-91
|
|
|
|
|
|
33) Khosla S, Burr D, Cauley J, et al; American Society for Bone and Mineral Research. Bisphos-phonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22: 1479-91
|
|
|
|
|
|
34) Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intra-venous bisphosphonates. J Bone Miner Res. 2008; 23: 826-36
|
|
|
|
|
|
35) Pazianas M, Blumentals WA, Miller PD, et al. Lack of association between oral bisphospho-nates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int. 2008; 19: 773-9
|
|
|
|
|
|
36) Odvina CV, Levy S, Rao S, et al. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol(Oxf). 2009; 6: 194-9
|
|
|
|
|
|
37) Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2008; 20: 1353-62
|
|
|
|
|
|
38) Abrahamsen B, Eiken P, Eastell R. Subtro-chanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009; 24: 1095-102
|
|
|
|
|